title: What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A viewpoint.
abstract: BACKGROUND
  Cochrane Reviews are methodologically of high quality but the clinical relevance of analysed efficacy measures (EMs) should also be assessed.
  
  
  METHODS
  The clinical relevance of EMs used in one systematic Cochrane review of oral zolmitriptan for migraine headache was evaluated.
  
  
  RESULTS
  The following EMs were used: pain free at two hours (30%), headache relief at two hours (60%), sustained pain free for 24 hours (19%) and sustained headache relief for 24 hours (39%). These EMs were also used in four other Cochrane reviews of acute migraine treatment. Of these EMs sustained headache relief for 24 h is not judged clinically relevant.
  
  
  CONCLUSIONS
  Pain free and sustained pain free are clinically relevant, but the responses are rather low, demonstrating that there is a need for improvement of acute drug treatment in migraine.
authors.affiliation: Danish Headache Center, University of Copenhagen, Department of Neurology, Glostrup Hospital Glostrup, Denmark d036218@dadlnet.dk.
authors.forename: Peer
authors.initials: P
authors.lastname: Tfelt-Hansen
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care / Q000592:standards*; D012196:Review Literature as Topic
keywords: Migraine; acute treatment; efficacy measures; triptans